Peanut allergy cured in majority of children in immunotherapy trial – The Guardian
The Guardian |
Peanut allergy cured in majority of children in immunotherapy trial
The Guardian A small clinical trial conducted at the Murdoch Children’s Research Institute has led to two-thirds of children treated with an experimental immunotherapy treatment being cured of their allergy. Importantly, this desensitisation to peanuts persisted … Australian Scientists Are On The Path To A Peanut Allergy CureGizmodo Australia Researchers unlock possible peanut allergy cureTen Eyewitness News Peanut allergy cure in sightThe West Australian |
West Hartford News |
Rare leukemia targeted by modifying patients’ immune cells
West Hartford News Turning the T cells into CAR–T cells helps by targeting the CD19 marker on the B cells. “CD19 happens to be a pretty good target for cancer technology because it’s only on B cells,” Gore said. “These new CAR–T cells latch onto the leukemia cells.”. |
OncLive |
Dr. Slovin on Approaches of Immunotherapy in Prostate Cancer
OncLive It’s important to recognize that immunotherapy encompasses more than checkpoint inhibitors, explains Slovin. There is a wide variety of other approaches that fall under the category of immunotherapy, such as antibodies, chimeric antigen receptor T … |
OncLive |
Dr. Slovin on Approaches of Immunotherapy in Prostate Cancer
OncLive It’s important to recognize that immunotherapy encompasses more than checkpoint inhibitors, explains Slovin. There is a wide variety of other approaches that fall under the category of immunotherapy, such as antibodies, chimeric antigen receptor T … |
|
Favorable Safety Profile Seen in Immunotherapy Drug in Aggressive Form of Lung Cancer
Newswise (press release) Newswise — New Brunswick, N.J., August 16, 2017 – The immunotherapy drug pembrolizumab has demonstrated a favorable safety profile and “promising durable clinical activity” in pretreated patients who exhibit high levels of the PD-L1 protein in … |
|
Immunotherapy Company’s Q2 Revenue ‘Handily Beats’ HC Wainwright’s Projection
Streetwise Reports (registration) Selvaraju reminded investors of revenue expected from another corporate partnership, this one with ApolloBio, for development in China of Inovio’s DNA-based, nonsurgical immunotherapy, VGX-3100. This deal “involves an upfront payment of $15M and an … |